THIRD-QUARTER 2025 RESULTS $5.4B MEDICAL DEVICES $1.5B ESTABLISHED $2.2B NUTRITION $5.12 to $5.183 REAFFIRMED FULL-YEAR GUIDANCE TOTAL COMPANY SALES $11.4B +7.5%1 Organic* sales growth for underlying base business** ADJUSTED DILUTED EPS $1.302 KEY BUSINESS UNITS ADJUSTED DILUTED EPS Narrowed range reflects double-digit growth at the midpoint 7.5% to 8.0%3 ORGANIC SALES GROWTH Excluding COVID-19 testing-related sales BUSINESS HIGHLIGHTS EXPANDING ALTERNATIVES TO OPEN-HEART SURGERY EXTENDING GLOBAL REACH OF S ...

（原标题：医疗器械业务加速但诊断"失速" 雅培(ABT.US)业绩不及预期） 智通财经APP获悉，美国医疗保健领域领导者雅培(ABT.US)在美股周三盘前所公布的季度营收低于华尔 街分析师预期，主要因市场对其医疗器械产品的强劲需求未能抵消其医疗诊断与营养品业务的疲弱趋 势。在业绩指引中，该公司管理层小幅下调每股收益展望上限，凸显特朗普政策不确定性带来的负面预 期。受到最新业绩带来的负面影响，该公司股价在美股盘前交易中下跌近3%。 该公司表示，现在预计全年调整后每股收益将在5.12美元至5.18美元区间，相比之下先前的区间则为 5.10美元至5.20美元，凸显出雅培管理层因关税与监管政策不确定性二下调每股收益上限预期。 上个月，特朗普政府根据《美国反垄断法》第232条对医疗器械进口展开全面调查，引发了对于该行业 征收新关税的可能性，并加强了对外国医疗供应链体系的审查。该公司还表示，其此前对今年关税影响 规模低于 2 亿美元的预期没有变化。 雅培Q3医疗器械业务的高景气(如糖尿病与心血管器械)虽稳健，但是未能完全对冲上述拖累。此外，雅 培业绩指引微幅收窄/重申销售额中枢，说明该公司业绩层面的问题更多是产品组合与周 ...

1. 10月15日(周三)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.56%，标普500指数期货涨0.76%，纳指期货涨0.99%。 | ■ US 30 | 46,527.50 | 46,558.20 | 46,270.00 | +257.00 | +0.56% | | --- | --- | --- | --- | --- | --- | | ■ US 500 | 6,694.80 | 6,700.90 | 6,643.50 | +50.50 | +0.76% | | ■ US Tech 100 | 24,823.60 | 24,851.40 | 24,568.80 | +244.30 | +0.99% | 2. 截至发稿，德国DAX指数涨0.02%，英国富时100指数跌0.38%，法国CAC40指数涨2.30%，欧洲斯托克50指数涨1.28%。 个股消息 摩根士丹利(MS.US)Q3业绩全线超预期，投行业务反弹成亮点，股票业务贡献核心动能。摩根士丹利第三季度净营收182.2亿美元，同比增 长18%，超出预估166.4亿美元;第三季度每股收益2.80美元，股本回报率18%，超出预估13.4%。其 ...

Core Insights - Abbott Laboratories reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales, slightly missing sales expectations of $11.39 billion [1][2] - The company reaffirmed its sales guidance for 7.5% to 8% organic sales growth for the year, excluding the impact of Covid tests, and narrowed its earnings outlook to a range of $5.12 to $5.18 per share [2] Financial Performance - In the same quarter last year, Abbott earned $1.21 per share on $10.64 billion in sales, indicating a year-over-year earnings increase of approximately 7.4% and sales growth of about 6.9% [2] - Analysts projected an average earnings per share of $5.15 and total sales of $44.69 billion for the year [2] Stock Market Reaction - In premarket trading, Abbott's stock fell nearly 3% to $128.94, breaking out of a cup-with-handle base with a buy point at $134.71 [3] - The stock is currently below the 5% chase zone and facing resistance at its 50-day moving average [3]

Core Insights - Abbott missed analysts' estimates for third-quarter revenue, reporting total revenue of $11.37 billion, slightly below the expected $11.40 billion, leading to a 3% drop in shares premarket [1][2]. Revenue Breakdown - Diagnostics segment sales fell 6.6% to $2.25 billion, missing the estimate of $2.29 billion, primarily due to a decline in COVID-19 testing demand [3]. - Medical devices segment sales increased 14.8% to $5.45 billion, driven by strong demand for continuous glucose monitors and heart devices [3]. External Factors - The halt of foreign aid has disrupted the supply chain for medical products and diagnostic tests in low-income countries, impacting Abbott's operations [2]. - Abbott is facing pricing pressure from China's procurement program, which purchases medical devices in bulk at significant discounts [2]. Profitability - On an adjusted basis, Abbott reported a third-quarter profit per share of $1.30, aligning with analysts' expectations [4]. - The company revised its annual adjusted profit forecast to a range of $5.12 to $5.18 per share, slightly down from the previous range of $5.10 to $5.20 [4].

The company narrowed its guidance for the second time this year. ...

Abbott cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration launched an investigation into the medical device sector https://t.co/R5qPn9BmKV ...

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults ...

(Reuters) -Abbott's quarterly revenue fell short of analysts' expectations on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices. Shares of the company dropped nearly 3% premarket following the results. Abbott's total revenue of $11.37 billion, slightly missed analysts' average estimate of $11.40 billion, according to data compiled by LSEG. Sales in its diagnostics segment fell 6.6% to $2.25 billion, missing the estimate of $2.29 b ...

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous glucose monitors and heart devices. ...